Mirum Pharmaceuticals, Inc. reported $618M of revenue over the trailing twelve months, +44% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $618M (to Q2 2026). Net income: −$860M, trailing twelve months to Q2 2026. Free cash flow: −$229M, trailing twelve months to Q2 2026. Operating margin: −130%, trailing twelve months to Q2 2026.

MIRMMirum Pharmaceuticals, Inc.

Healthcare

$85.96+16% 1Y

$85.96

$64.1052 weeks$122.04

MIRM as reported

Mirum Pharmaceuticals, Inc. reported $618M of revenue over the trailing twelve months, +44% on the year before. 8 reported series are charted on this page, each one as filed.

$618M

Revenue, trailing twelve months · to Q2 2026 · +44% against the twelve months before

Net income: −$860M
Net income · +1369% year on year · trailing twelve months to Q2 2026
Free cash flow: −$229M
Free cash flow · −2751% year on year · trailing twelve months to Q2 2026
Operating margin: −130%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MIRM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$618M	+44%	Q2 2026
Net income	−$860M	+1369%	Q2 2026
EPS	−$14.56	+1103%	Q2 2026
Operating margin	−130%	n/a	Q2 2026
Net margin	−134%	n/a	Q2 2026
ROE	1976%	n/a	Q2 2026
ROA	−45%	n/a	Q2 2026
Free cash flow	−$229M	−2751%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.